A study of cell surface phenotypes of PBL of myasthenia gravis (MG) patients showed that their T cells had a significantly higher percentage of 4B4+ T cells (the helper/inducer subset) than age-and sex-matched controls. The PBL of MG patients proliferated significantly higher than those of normal subjects (NS) in response to the purified a chain of the acetylcholine receptor (AChR). Anti 
Introduction
Myasthenia gravis (MG)' is thought to be an autoimmune disease primarily mediated by antibodies to the acetylcholine receptor (AChR) (1, 2) . The severity of the disease, however, does not correlate well with serum antibody levels (2) . Many studies, including ours, have found that T cells from the peripheral blood of MG patients respond, by lymphoproliferation, to AChR or AChR synthetic peptides, to a greater extent than do T cells from normal subjects (3) (4) (5) (6) . T cell lines responsive to AChR and/or its peptides have been isolated from thymus as well as blood of MG patients (7) (8) (9) (10) . These lines, however, were all obtained by in vitro culture of T cells with antigens. Thus, the specific function of these T cells and their involvement in the regulation of autoantibody production have not been fully elucidated.
This study was undertaken to characterize the peripheral blood lymphocytes (PBL) of MG patients both phenotypically and functionally in order to assess the immunoregulatory role of T cells in the pathogenesis of MG. With the availability of new monoclonal antibodies, CD4 and CD8 subsets of T cells have been found to be both functionally and phenotypically heterogenous (11) (12) (13) . Through the use of monoclonal antibodies to CD4, CD8, 2H4, and 4B4 antigens, the T cells in PBL were further identified by the flow cytometry technique as supressor-inducer(2H4+) or helper-inducer(4B4+) subsets. Clones of T cells were established from PBL of MG patients in the absence of the putative antigen, AChR, to exclude in vitro sensitization to AChR. The aim of this study is to determine the function of these T cells and their possible role in the pathogenesis of MG.
Methods
MG patients and controls for phenotypic studies. The clinical features of 17 patients with generalized MG, studied for phenotypic characterization, are shown in Table I . Three had mild weakness at the time of study, nine had moderate weakness, and five were severely weak and had difficulty breathing, swallowing, or getting out of bed. Three had previously had thymectomy, and two thymomectomy. Six were receiving prednisone daily. Only one patient (E.K.) was receiving azathioprine, 100-150 mg daily orally, for 3'/2 mo. None had received plasmapheresis within a year ofstudy. All except two patients had elevated serum levels of antibody to AChR, varying from 1 to 369 nmol/liter. Nine normal subjects and 10 patients with multiple sclerosis (MS) of similar age and sex distribution were studied as controls. MS is an autoimmune disease of the central nervous system that has been phenotypically characterized and is thought to be a T cell-mediated disease.
Purification ofAChR. The AChR was purified from the tissues of Torpedo californica according to a previously described method (14, 15) . After purification, the antigen was concentrated by ultrafiltration using a cell concentrator (Omega, Filtron, Clinton, MA). The purity of the recovered material was analyzed by SDS-PAGE on 7.5% gels under reducing conditions. One prominent band was seen in the area of 40,000-50,000 mol wt, which corresponded to the a chain of the receptor (Fig. 1) . The presence ofother AChR chains, however, cannot be ruled out completely (14, 15) . Before use in cell culture studies, the antigen was dialyzed against 0.01 M phosphate-buffered saline (PBS), pH 7.2, to remove the detergent and the enzyme inhibitors. The purified a chain had a specific activity of l0' M a-bungarotoxin binding sites per milligram of protein, as determined by a '25I-a-bungarotoxin binding assay. The purified AChR has been used to induce experimental autoimmune MG in rats (14, 15) .
Anti-AChR antibody assays ofsera. Sera from patients with MG and from normal subjects were assayed for anti-AChR antibody, using '251-ca-bungarotoxin-labeled human AChR (16). This assay was performed by SmithKline Bioscience Inc., Sunnyvale, CA, and the titers Production ofanti-AChR-a chain antibody in vitro. Purified T cells (2 X 104/ml) from 29 MG patients, 10 MS patients, and 10 normal subjects and their purified autologous B cells (5 X 104/ml) were cultured, either alone or together, in the presence of 10 ,ug/ml AChR-a chain or 12.5 Ag/ml pokeweed mitogen (PWM, Sigma Chemical Co.).
The cells were cultured for 9 d in culture medium in 96-well roundbottomed microtiter plates (20) . Cultures containing AChR were incubated for 4 d, at which time the medium was removed, to remove free AChR which might combine with the synthesized antibody, and recultured in antigen-free medium for S d. At the end of culture, the supernatants were harvested and concentrated 50-fold, using B 15 concentrators (Amicon Corp., Danvers, MA) and stored at -800C until tested for anti-AChR-a chain antibody. 0
Measurement of anti-AChR-a chain antibody produced in vitro. The anti-AChR-a chain antibody was measured by a sensitive enzyme-linked immunosorbent assay (ELISA), in which the microtiter wells were coated with AChR-a chain (I ,g/ml) or control antigen, myelin basic protein (MBP). This MBP, routinely purified in our laboratory from guinea pig spinal cords, is being successfully used to determine antibody in the sera of mice and MS patients (21 (24) . 24 replicate cultures were set up for each cell concentration and incubated at 37°C in 5% C02/95% air. The cultures were fed on day 7 by replacing 0.1 ml ofgrowth medium with fresh IL-2 containing medium. After a further 7 d in culture, the microtiter wells were scored microscopically and the ones that contained growth were picked and expanded in fresh IL-2 medium. Cultures in which growth was seen in the control feeder cells alone were discarded. Poisson distribution analysis was used to identify those populations arising from single precursors (i.e., input cell density giving > 37% negative wells). Therefore clones were picked from less than one cell per well for this study. In many instances, when an already established clone was very small or was not growing well, 5 Mg/ml of phytohemagglutinin (PHA), together with feeder cells, was added to the culture. The clones were fed with fresh medium every 2-3 d and feeder cells plus PHA (5 gg/ml) when their growth had stopped. After 8 wk in culture, the growth and functional properties of most clones started to decline.
Phenotyping of T cell clones. The surface antigenic phenotype of PBL and T cell clones were tested by an immunofluorescence assay using mouse anti-human CD4, CD8, 2H4, and 4B4 MAb (Coulter Immunology, Hialeah, FL). PBL (1 X 106) and T cell clones ( give effector/target ratios of 5:1, 10:1, and 20:1. The tubes were centrifuged at 45 g for 3 min and incubated at 37°C in 5% CO2 for 4 h. Maximum and spontaneous release of 5'Cr was determined by adding respectively 100 Al of 2% Triton-X 100 and medium alone to the targets. After incubation, the tubes were centrifuged at 150 g for 10 min and 100 Ml of supernatant was removed and counted for radioactivity in a Beckman 5500 B y-counter (model 5500B, Beckman Instruments, Inc., Fullerton, CA). In all experiments the spontaneous release was always < 10% of the maximum release. The results are expressed as: % specific cytotoxicity = (test release -spontaneous release X 100)/ (maximum release -spontaneous release).
Results
Phenotypic analysis of PBL. The surface phenotypes of the PBL of 17 MG patients (described in Table I ) and 19 controls (9 normal subjects and 10 patients with MS) are listed in Tables II and III , respectively. Patients with MG did not differ from normal subjects and MS patients in the percentage of CD4 and CD8 cells in their PBL. MG patients, however, exhibited a significantly higher percentage of 4B4+ cells, the helper-inducer subset, than normal subjects (P < 0.001). The percentage of 2H4+ cells, the cytotoxic/suppressor-inducer subset, though lower than in normal subjects, was not significantly different (Table II) . In contrast, the percentage of 2H4+ cells in MS patients was significantly lower (P = 0.01) than in normal subjects, whereas the percentage of 4B4+ cells was not significantly different (Table III) severe weakness. The latter group of patients, however, were all receiving daily prednisone, which can affect their percentage of responding cells (Tables I and II) .
Peripheral blood humoral and cellular responses to AChR. Antibody to AChR was significantly elevated in the sera of 15 of 17 (88%) of MG patients (Table II) and none of 9 normal subjects, who consistently had a level of < 0.5 nmol/liter (data not shown). Patients with severe MG of shorter duration displayed the highest levels of anti-AChR antibody in their sera (Table II) .
The lymphoproliferative responses to purified AChR-a chain of PBL from 17 patients with MG and 11 normal subjects are presented in Fig. 2 . Any cpm > 3 X 103 (mean normal subjects + 2 SD) was considered to be significantly elevated.
The PBL of 11 MG patients (65%) and one normal subject (9%) proliferated to AChR above this level (Fig. 2) .
To study the separate roles of T and B cells in the production of antibody to AChR-a chain, these cells were separated, purified, and cultured either separately or together, in the presence of either AChR or PWM and antibody production was measured (Fig. 3) . Detectable amounts of anti-AChR-a chain antibody were produced only when autologous T and B cells from MG patients were cultured together. The level of antiAChR antibody synthesis was higher with the T cell-dependent B cell polyclonal activator, PWM, than with AChR-a chain. Purified T cells from PBL of 11 (Fig. 3) . Unseparated PBL from 3 of 29 MG patients (10%), when stimulated with AChR-a chain, and 13 of 29 MG patients (45%), when stimulated with PWM, produced slightly elevated levels of anti-AChR-a chain antibody in the culture supernatants (Fig. 3) . The antibody, synthesized in vitro, was specific for AChR-a chain since it did not bind to the irrelevant antigen, MBP. Anti-AChR-a chain antibody was not detectable in supernatants from cultures of PBL of normal subjects and MS patients (Fig. 3) . Culture supernatants from T or B cells alone of MG patients, stimulated with either AChR-a chain or PWM, all gave values of < 1 ng/ml of antiAChR antibody, which did not differ from the concentration of unstimulated T or B cell cultures of MG patients (data not shown).
Generation ofIL-2 responsive T cell clones. PBL from nine patients with MG and eight normal subjects were cloned by LDA in IL-2 medium without prior activation with AChR-a chain. Most cultures from patients with MG yielded some growth at less than one cell per well while cultures from normal subjects required 200-400 cells per well (Table IV) . Thus, MG patients had a much higher precursor frequency of IL-2-responsive cells than normal subjects, and hence could be Fig. 4 . The linear regression ofthe curves, plotted as number of cells against the logarithm of the fraction of nonresponsive cultures (Fnr) indicates that precursors of IL-2-responsive T cells were limiting in these cultures. This profile is consistent with a single-hit phenomenon (26) . Thus, by applying Poisson distribution analysis, the precussor frequency or likelihood of monoclonability could be determined from the line at Fnr = 0.37, at one cell per well for MG patients and at 400 cells per well for normal subjects. Since the MG clones were picked and expanded from less than one cell per well, the majority, but not all of the growth obtained was considered monoclonal.
When tested by FACS, 85% of T cell clones from MG patients were found to be 2 95% homogenous (either CD4 or CD8), whereas only -20-30% of cell growth in cultures of lymphocytes from normal subjects were homogeneous and the rest had to be either recloned or discarded. Multiple attempts had to be made in order to obtain T cell clones from normal subjects under our experimental conditions. Phenotypic analysis of T cell clones. 14 of the 21 T cell clones (70%) obtained from 9 MG patients expressed CD8 antigens, and 7 (30%) expressed CD4 on their surfaces (data not shown). The surface phenotypes of the nine clones from seven MG patients which were responsive to AChR-a chain in the lymphoproliferation assay (see below), are shown in Table  V . Of these nine clones, five were CD4+ and four were CD8+. The surface phenotype of the T cell clones obtained from five normal subjects was predominantly CD8 (8/9 or 90%), with CD4 antigen being expressed on only one clone (1/9 or 10%). The clones were further analyzed for the expression of 2H4 and 4B4 antigens, which define the supressor-inducer and helper-inducer subsets, respectively. Five of nine clones from MG patients and four of nine from normal subjects expressed only 4B4 antigen on their surface (Table V) . Three of nine clones from MG patients and three of nine from normal subjects expressed both 4B4 and 2H4 antigens on their surface. A clone from one normal subject and none from MG patients expressed 2H4 antigen in the absence of 4B4 antigen, and one clone from each group expressed only CD8 antigen.
Proliferative responses of T cell clones to AChR. 19 T cell clones isolated from 9 patients with MG, and 9 clones from 8 normal subjects were stimulated with purified AChR-a chain, IL-2, and MBP. Of the 19 T cell clones, nine from seven different MG patients proliferated significantly to purified AChR-a chain ( Table VII ). None of the MG clones proliferated against MBP (Table VI) , suggesting that the clones exhibited specificity to AChR-a chain. Clones from both MG patients and normal subjects also proliferated to rIL-2, indicating their IL-2 responsiveness (Table VI) . The clones were also tested for allospecific proliferative responses to AChR-a chain, using both autologous and alloge- neic APC. The average proliferative response of T cell clones from MG patients, in the presence of autologous APC, was significantly higher than that of T cell clones from normal subjects (Fig. 5) . The positive proliferative response only occurred when AChR-a chain was presented with autologous APC, suggesting that the recognition of AChR-a chain by the MG clones was MHC restricted (Fig. 5) . As shown in one representative experiment, the allogeneic APC obtained from one MS patient failed to elicit proliferation of MG clones to AChR-a chain but was capable of presenting MBP to T cell clones from the same MS patient (Table VII) . About 10% of all clones produced "allogeneic" response with an average cpm of 1-3 X 103. None of these were antigen responsive and all were excluded from this study. To further define the nature of the MHC restriction of AChR-a chain-specific clones, antibodies to HLA-DR and HLA-ABC were added during the 72-h assay. Anti-HLA-DR but not anti-HLA-ABC inhibited the proliferation of two clones, indicating that they were class-II restricted (Fig. 6 ). Cytotoxic activity of T cell clones. Nine T cell clones from patients with MG, eight from normal subjects and eight from patients with MS were examined for non-MHC restricted cytotoxicity by their capacity to kill K562 and Daudi target cells (Fig. 7) . T cell clones from MG patients, MS patients, and normal subjects were not significantly different from each other in their levels of cytotoxicity against K562 target cells. T cell clones from MG patients were significantly less cytotoxic against Daudi cells than the clones from MS patients (P < 0.03) and marginally less cytotoxic than the T cell clones from normal subjects (P = 0.05).
Discussion
In this report, the phenotypic and functional characteristics of peripheral blood T cells were studied to evaluate the regulatory role of T cells in the pathogenesis of MG. First, the cell surface phenotypes of the PBL of MG patients were analyzed and it was found that MG patients had a significantly higher percentage of the helper-inducer subset of T cells (4B4+) than normal subjects. Recent studies have indicated that the CD4+ and 2104 Mokhtarian et al. CD8+ populations of T cells can be subdivided into two dis-serum antibody level was higher in 88% of the MG patients tinct subsets, 2H4+4B4-and 2H4-4B4+, using monoclonal than in normal subjects. Anti-AChR antibodies and their antibodies and functional studies (11) (12) (13) . The former subset pathologic role in MG have been studied extensively (29). In suppressed PWM-driven Ig synthesis and was hence desigvitro synthesis of anti-AChR antibodies in cultures of unstimnated suppressor-inducer, whereas the latter subset functioned ulated and PWM -stimulated PBL was shown to be signifias a classical helper cell. Our findings in MG are in contrast to cantly higher in MG patients than in normal controls (30) . The those in patients with MS and rheumatoid arthritis, in whom mechanisms responsible for the emergence and regulation of the percentage of suppressor-inducer cells (2H4+) was signifithis autoantibody are not yet understood. Our studies indicate cantly lower than in normal subjects (27, 28) . Although the that PBL B cells from MG patients secreted antibody to percentage of suppressor-inducer T cell subset in patients with AChR-a chain in vitro, only when cultured with autologous T MG was also lower than in normal subjects, this difference was cells. The lymphoproliferative response of MG PBL to Tornot statistically significant.
pedo AChR-a chain, was higher than PBL from normal subThe cellular and antibody responses of MG patients and jects. 65% of PBL from MG patients showed proliferative renormal subjects to the a chain of AChR were analyzed. The sponses to this antigen, compared with 9% of normal subjects. (6) , indicating the heterogeneity of the response.
In this study, 9 of 19 T cell clones, obtained from seven MG patients, exhibited positive proliferative responses to purified AChR-a chain from Torpedo californica. This data is consistent with results obtained by other investigators (7) (8) (9) (10) . None of the clones responded to the irrelevant antigen, BSA, or to another autoantigen MBP, suggesting an antigen-specific recognition by the clones. None of the nine T cell clones obtained from eight normal subjects proliferated to the AChR-a chain. Hohlfeld et al. MG patients in the presence of Torpedo AChR. Using three synthetic peptides corresponding to the NH2 terminal of human AChR, they found that different peptides were recognized by different T cell lines, indicating that the T cell autoimmune response in MG is heterogenous (7). Melms et al. (10) , also using Torpedo AChR, isolated CD4+ T cell lines from thymuses of MG patients. All of these studies (7) (8) (9) (10) have used T cell lines rather than clones. Using the LDA (23) in the presence of rIL-2 and in the absence of putative autoantigen, AChR, we isolated antigen-reactive T cell clones only from the PBL of MG patients and not from the PBL of normal subjects. This is at variance with the findings of others (4, 5) who isolated T cell lines with low reactivity to AChR from normal human blood. In these studies, however, the MNC were stimulated with AChR before establishing the T cell line and so it is difficult to infer whether the AChR-reactive cells obtained during culture were generated from naive T cells or were the result of the expansion of preexisting reactive cells in the starting population.
In the present study, we have demonstrated, for the first time, that AChR-responsive CD4+ and CD8+ T cell clones can be isolated and expanded in vitro only from the peripheral blood of MG patients and not from normal subjects. The technique employed for the generation of T cell clones appears to be preferable to other techniques for studies on autoreactive T cells in autoimmune diseases. The technique employed, however, selected for CD8+ T cell clones in the PBL of normal subjects and, to a lesser extent, of MG patients. While CD4 T cells are more than twice as numerous as CD8 T cells in PBL of both MG patients and normal subjects, the clones that were obtained were 90% CD8 in normal subjects and 44% in MG patients. This may be due to selective pressures in the culture system, such as the presence of rIL-2 as the only lymphokine, which facilitates the growth of CD8+ cells over CD4+ cells. T cell clones from MG patients and normal subjects were further analyzed for the expression of surface antigens, 4B4 and 2H4. About 50% of T cell clones from each group were found to be 4B4+ and 33% were positive for both antigens. It is quite clear, from other studies as well, that the expression of these two antigens on the surface of T cells is not mutually exclusive (31) . Other expression of 4B4. These studies, however, used purified CD4+ cells and PHA, which being a polyclonal T cell mitogen will presumably cause the maturation of naive T cells. In contrast, our studies used only IL-2 to select for spontaneously activated T cells which may be differentiating further in vitro.
The precursor frequency of IL-2-responsive clones was much higher in MG patients than normal subjects, indicating that MG patients may have a larger pool of spontaneously activated cells in the PBL which can readily be cloned with high frequency. Our findings also suggest that long-term IL-2-dependent T cell clones can retain their antigen reactivity through activation with PHA and APC in the absence of the putative antigen. This is consistent with other studies which have shown that T cells maintained on APC and IL-2 alone, and/or on CD3 antibody, retained their antigenic specificity and reactivity (33, 34) .
The MG clones in this study did not exhibit significant non-MHC restricted cytotoxicity, as compared to the controls, in being able to kill K562 (NK-sensitive) and Daudi (NK-resistant) targets. This finding is in contrast with the findings of others that CD4+ and CD8+ T cell clones activated with PHA (35), or cloned in IL-2 medium, express non-MHC-restricted cytotoxicity (36, 37) in being able to kill a variety of tumor targets. In our laboratory, we have found that IL-2-responsive clones obtained from MS patients expressed non-MHC-restricted cytotoxicity (manuscript submitted for publication). The absence of significant cytotoxic activity in T cell clones from MG patients suggests that the PBL T cells play their role in the pathogenesis ofMG, not by cytotoxicity, but more likely by their demonstrated ability to stimulate antibody production by B cells.
Based on previous studies on cloned normal T cell populations, these cells could be grouped into at least two types. One helped specific B cell responses, but failed to mediate killing and suppression of delayed-type hypersensitivity, while the other suppressed specific antibody response, mediated delayed-type hypersensitivity and killed appropriate target cells (38) . These functional distinctions have led to the designation of the first set as helper T cells/TH2 and the latter as inflammatory T cells/TH . Using anti-CD45R antibody, these two functional populations were found to be CD45R-low (or 4B4+ in humans) in helper and CD45R-high (2H4+ in humans) in inflammatory subset of T cells (38) .
In summary, T cells from MG patients expressed a higher density of 4B4 antigen than normal subjects and were much more readily cloned than T cells of normal subjects. The MG T cell clones were highly proliferative to AChR-a chain, the putative autoantigen, helped the production of specific antiAChR antibody by autologous B cells, but did not express significant cytotoxic activity against target cells. T cell clones from normal subjects did not proliferate or make antibody, in similar experiments, to AChR-a chain. It appears that the T cells from MG patients are of TH2/helper category. Based on the above observations, the two phenotypically and functionally different subpopulations of T cells which exist in vivo for both CD4 and CD8 T cells, 4B4 and 2H4, probably play major roles in the immunoregulatory circuit (39) . Changes in the proportions and numbers of these antigen-activated cells may be major factors in the pathogenesis of myasthenia gravis and perhaps other autoimmune diseases.
